Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAZZNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAZZJazz Pharmaceuticals$107.82-0.4%$113.50$95.49▼$148.06$6.65B0.38847,237 shs863,792 shsZYMEZymeworks$11.48-3.9%$11.78$8.21▼$17.70$798.74M1.24597,696 shs479,860 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAZZJazz Pharmaceuticals-0.42%+1.65%+4.29%-20.73%+2.19%ZYMEZymeworks-3.85%-0.43%-5.59%-20.22%+27.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAZZJazz Pharmaceuticals4.9141 of 5 stars4.51.00.04.03.53.33.1ZYMEZymeworks3.3609 of 5 stars4.50.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAZZJazz Pharmaceuticals 2.93Moderate Buy$182.7969.53% UpsideZYMEZymeworks 2.90Moderate Buy$21.0082.93% UpsideCurrent Analyst Ratings BreakdownLatest ZYME and JAZZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/7/2025JAZZJazz PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.005/7/2025JAZZJazz PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.005/7/2025JAZZJazz PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.005/7/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$183.00 ➝ $166.005/7/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.00 ➝ $200.004/10/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$210.00 ➝ $210.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025JAZZJazz PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$200.00 ➝ $217.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAZZJazz Pharmaceuticals$4.06B1.63$21.96 per share4.91$59.36 per share1.82ZYMEZymeworks$93.38M8.55N/AN/A$6.63 per share1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAZZJazz Pharmaceuticals$414.83M$7.5015.195.761.0411.60%29.30%9.72%7/30/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)Latest ZYME and JAZZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAZZJazz Pharmaceuticals1.464.263.74ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAZZJazz Pharmaceuticals89.14%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipJAZZJazz Pharmaceuticals4.20%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAZZJazz Pharmaceuticals3,20061.63 million57.92 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableZYME and JAZZ HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust CorpMay 23 at 3:09 AM | marketbeat.comZymeworks (NYSE:ZYME) Research Coverage Started at TD SecuritiesMay 23 at 2:41 AM | americanbankingnews.comZymeworks (NYSE:ZYME) Earns Buy Rating from Analysts at TD CowenMay 23 at 1:59 AM | americanbankingnews.comZymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical ConferencesMay 22 at 5:00 PM | globenewswire.comTD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME)May 22 at 8:31 AM | marketbeat.comPoint72 Asset Management L.P. Boosts Stock Position in Zymeworks Inc. (NYSE:ZYME)May 22 at 4:42 AM | marketbeat.comZymeworks (NYSE:ZYME) Stock Price Up 4.2% After Insider Buying ActivityMay 22 at 1:33 AM | americanbankingnews.comZymeworks Inc. Presents Promising Preclinical Data for ZW1528, a Novel Bispecific Antibody Targeting IL-4Rα and IL-33 for Respiratory InflammationMay 21 at 4:05 PM | nasdaq.comZymeworks Inc. (NYSE:ZYME) Stake Lessened by Vestal Point Capital LPMay 21 at 8:14 AM | marketbeat.comTD Securities Initiates Coverage of Zymeworks (ZYME) with Buy RecommendationMay 21 at 6:48 AM | msn.comTD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer TherapyMay 21 at 6:48 AM | msn.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 21 at 6:00 AM | globenewswire.comZymeworks Inc.: Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 20 at 10:43 AM | finanznachrichten.dePolar Asset Management Partners Inc. Buys New Holdings in Zymeworks Inc. (NYSE:ZYME)May 20 at 5:29 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 5,919 SharesMay 20 at 5:17 AM | insidertrades.comZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 19, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Prosight Management LPMay 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.21 Million Position in Zymeworks Inc. (NYSE:ZYME)May 17, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Buys Shares of 22,800 Zymeworks Inc. (NYSE:ZYME)May 15, 2025 | marketbeat.comWall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a BetMay 14, 2025 | zacks.comAnalyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging HigherMay 14, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME and JAZZ Company DescriptionsJazz Pharmaceuticals NASDAQ:JAZZ$107.82 -0.45 (-0.42%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$109.50 +1.68 (+1.55%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Zymeworks NYSE:ZYME$11.48 -0.46 (-3.85%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$11.27 -0.21 (-1.82%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
